Detailed description page of B3Pdb


This page provides detail information of Selected ID b3pdb_0069
Primary information
B3PDB IDb3pdb_0069
Peptide NameCyclic ADTHAV
PEPTIDE SEQUENCE (1-letter)TPPVSHAV
PEPTIDE SEQUENCE (3-letter)ThrProProValSerHisAlaVal
N-terminal modificationNA
C-terminal modificationNA
Chemical modificationNA
Peptide Length8
ConformationCyclic
Peptide NatureNA
Source/Origin of peptideChemically synthesized
SMILESN[C@@]([H])([C@]([H])(O)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C(C)C)C(=O)O
Cell LineNA
In vitro CONCENTRATIONNA
In vitro METHODNA
In vitro RESULTNA
ANIMAL MODELC57BL6 mice
In vivo CONCENTRATIONNA
In vivo MODE OF DELIVERYIntracerebral ventricular
In vivo METHODMass Spectromtery
In vivo RESULTIt is able to deliver an IRdye800CW-labeled IgG monoclonal antibody into the brain.
ACTIONSynthesized novel cyclic peptides are able efectively modulate the BBB to enhance the delivery of mA
TRANSPORT TYPENA
SUBCELLULAR LOCALISATIONNA
COMBINATIONCombined with monoclonal antibody
PHYSICAL CONDITIONNA
RESPONSENA
RESULTNA
LABELNA
PMID31683745